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A B S T R A C T
Purpose
Previous studies have suggested that higher plasma 25-hydroxyvitamin D3 [25(OH)D] levels
are associated with decreased colorectal cancer risk and improved survival, but the prevalence
of vitamin D deficiency in advanced colorectal cancer and its influence on outcomes
are unknown.
Patients and Methods
We prospectively measured plasma 25(OH)D levels in 515 patients with stage IV colorectal cancer
participating in a randomized trial of chemotherapy. Vitamin D deficiency was defined as 25(OH)D
lower than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as  30 ng/mL. We
examined the association between baseline 25(OH)D level and selected patient characteristics.
Cox proportional hazards models were used to calculate hazard ratios (HR) for death, disease
progression, and tumor response, adjusted for prognostic factors.
Results
Among 515 eligible patients, 50% of the study population was vitamin D deficient, and 82% were
vitamin D insufficient. Plasma 25(OH)D levels were lower in black patients compared to white
patients and patients of other race (median, 10.7 v 21.1 v 19.3 ng/mL, respectively; P  .001), and
females compared to males (median, 18.3 v 21.7 ng/mL, respectively; P  .0005). Baseline plasma
25(OH)D levels were not associated with patient outcome, although given the distribution of
plasma levels in this cohort, statistical power for survival analyses were limited.
Conclusion
Vitamin D deficiency is highly prevalent among patients with stage IV colorectal cancer receiving
first-line chemotherapy, particularly in black and female patients.
J Clin Oncol 29:1599-1606. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Vitamin D insufficiency is highly prevalent in the
United States. Recent data indicate that 77% of
Americans have plasma 25-hydroxyvitamin D3
[25(OH)D] levels lower than 30 ng/mL, the thresh-
old required for adequate bone health.1 These low
levels of vitamin D are concerning in light of increas-
ing evidence that vitamin D may have health bene-
fits beyond skeletal outcomes, including reducing
the risk of and mortality from colorectal cancer.2,3
Scientific observations support a role for vi-
tamin D in colorectal cancer pathogenesis, with
almost ubiquitous expression in colon cancer cells
of vitamin D receptors (VDR)4,5 and 1--
hydroxylase,6 which converts plasma 25(OH)D into
1,25-dihyroxycholecalciferol [1,25(OH)2D]. Binding
of VDR by 1,25(OH)2D leads to induction of differen-
tiation and apoptosis,7,8 and inhibition of prolifera-
tion,9 angiogenesis,10,11 and metastatic potential.12,13
Vitamin D also interacts with other pathways involved
in colorectal cancer, including the insulin-like growth
factor(IGF)pathway.Forexample,1,25(OH)2Dinflu-
ences mitogen-activated protein kinase (MAPK)
–extracellular signal-regulated kinase (ERK) sig-
naling through effects on IGF-1, and also induces
apoptosis through the IGF receptor-1 (IGFR-1)
–phosphatidylinositol 3-kinase (PI3K) –Akt sig-
naling pathway.14
Although two studies of patients with estab-
lished colorectal cancer found that higher 25(OH)D
levels were significantly associated with improved
survival,15,16 the vitamin D status of patients with
metastatic colorectal cancer specifically has not been
studied. We therefore examined a cohort of patients
with stage IV colorectal cancer enrolled in a large,
completed, Intergroup-sponsored clinical trial of
palliative chemotherapy, and sought to determine
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the prevalence of vitamin D deficiency and whether vitamin D status
was associated with improved treatment outcomes.
PATIENTS AND METHODS
Study Population
Patients included in this study were drawn from a national, Inter-
group trial of chemotherapy for metastatic colorectal cancer (N9741).
Patients were randomly assigned between October 1998 and April 2001 to
receive bolus fluorouracil, leucovorin, and irinotecan (IFL); infusional
fluorouracil, leucovorin, and oxaliplatin (FOLFOX); or irinotecan and
oxaliplatin (IROX). Full details and results of the treatment trial have
previously been published.17 Briefly, patients were required to have histo-
logically proven unresectable colorectal adenocarcinoma, Eastern Cooper-
ative Oncology Group performance status of 2 or lower, and adequate
renal, liver and bone marrow function. Exclusion criteria included prior
therapy for advanced disease, baseline peripheral neuropathy, or CNS
disease, uncontrolled or severe comorbid illnesses, and baseline  3 loose
stools per day. The protocol was reviewed and approved by the institu-
tional review board of each participating institution. Patients signed in-
formed consent for participation in the trial and were given the option of
inclusion in a companion study of plasma for future research.
In total, 1,379 patients were enrolled in N9741 after the incorporation of
an amendment to collect blood samples for companion biomarker studies. Of
these, 547 patients provided blood samples, with 515 available for this analysis.
Figure 1 illustrates the derivation of the final cohort size and reasons for
exclusion at different time points. Among the 515 eligible patients, 239 (46%)
had a confirmed tumor response. Since study enrollment, 440 patients (85%)
have progressed and 475 (92%) have died. The median time of follow-up
among living patients was 5.1 years (10th and 90th percentiles: 3.3 and 6.1
years, respectively). In a previous report, we compared baseline characteristics
of the overall cohort of patients who enrolled in the treatment trial with the
subset participating in the biomarker studies, and did not detect any apprecia-
ble differences between the two groups.18 Patients who did and did not provide
blood samples experienced similar overall survival (median 18.1 and 17.0
months, respectively).
Response and Progression Criteria
Study enrollment required at least one measurable lesion ( 2 cm in
diameter) or disease that could be serially evaluated to establish whether the
disease was getting better or worse (evaluable disease). Objective response to
chemotherapy was calculated among patients evaluable for response (n 
511), whereas time to progression and overall survival were assessed among all
subjects (n  515). Partial response required at least a 50% reduction in the
sum of the products of the longest perpendicular diameters of all measurable
lesions. Regression required documented tumor reduction in evaluable pa-
tients who did not have disease that met the guidelines for measurable disease.
Disease progression required  25% increase in measurable tumor or an
increase in tumor size in patients whose lesions did not meet criteria for
measurable disease. After partial response, tumor measurements exceeding
50% of the maximal extent of a previously observed reduction constituted
progression. Any new lesion constituted progression. Patients who did not
meet the definitions of response or progression were classified as having
stable disease.
Time to progression (TTP) was calculated from study entry to disease
progression, regardless of the patient’s treatment status. Deaths occurring
within 30 days of treatment discontinuation were considered progressions.
Survival was calculated from enrollment to death or last contact. Without
contradictory data, patients who died or were lost to follow-up were assumed
to have progressed at the time they were last documented to be progres-
sion free.
Plasma Biomarker Assessment
Blood samples were collected on study registration and sent to the Mayo
Clinic central laboratory for clinical trials (Rochester, MN). Whole-blood
samples for this analysis were cooled and sent by overnight delivery to Heart-
land Assays Inc (Ames, IA), and 25(OH)D concentrations measured by radio-
immunoassay.19 Masked quality control samples were interspersed among the
case samples, and all laboratory personnel were blinded to patient outcome.













Final sample size for
tumor response
(n = 511)
Randomly assigned to treatment arms
that were subsequently discontinued
(n = 183)
Enrolled prior to amendment for
plasma biomarker companion study
(n = 129)
Eligible, but did not consent to
plasma biomarker protocol
(n = 832)
Restricted use of blood sample
for main analysis of N9741 only
(n = 22)
Blood sample unavailable for 
vitamin D measurement
(n = 8)
Excluded from analysis due
to missing covariate data
(n = 2)
Fig 1. Derivation of cohort size. N9741,
Intergroup trial N9741; TTP, time
to progression.
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Table 1. Baseline Patient Characteristics (n  515)
Characteristic No. %
Median plasma 25(OH)D, ng/mL 20.0
Range 2.3-75.4









Asian, Native Hawaiian, other Pacific Islander 10 2





Missing 1  1











One metastatic site, not liver
Yes 40 8
No 475 92












Geographic region of registering site§
Northeastern US 73 14
Midwestern US 238 46
Southern US 80 16
Western US 58 11
Puerto Rico 7 2
Canada 48 9
Missing 11 2
Abbreviations: 25(OH)D, 25-hydroxyvitamin D3; ECOG, Eastern Cooperative Oncology Group; IFL, irinotecan, bolus fluorouracil, leucovorin; FOLFOX, fluorouracil,
leucovorin, oxaliplatin; IROX, irinotecan, oxaliplatin; US, United States.
A performance status of 0 indicates a patient was fully active; 1, restricted in physically strenuous activity but ambulatory and able to carry out light work; 2,
ambulatory and capable of all self-care but unable to carry out any work activities and up and about more than 50% of waking hours. Performance status was based
on patient status at initiation of chemotherapy (entry into treatment trial).
†Body mass index is calculated as weight in kilograms divided by height in meters squared. Body mass index was based on patient status at initiation of
chemotherapy (entry into treatment trial).
‡Seasons defined as: Summer  June, July, August; Autumn  September, October, November; Winter  December, January, February; Spring  March, April, May.
§Geographic regions defined according to the US Census Bureau: Northeast  CT, ME, MA, NH, NJ, NY, PA, RI, VT; Midwest  IL, IN, IA, KS, MI, MN, MO, NE,
ND, OH, SD, WI; South  AL, DE, FL, GA, KY, LA, MD, NC, OK, SC, TN, TX, VA, WV; West  AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.
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IGF-1, IGF-2, IGF binding protein (IGFBP) -3, and C-peptide levels
were assayed in the laboratory of Michael Pollak, MD (Jewish General Hospi-
tal, McGill University, Montreal) using enzyme-linked immunosorbent as-
says, as previously described.20
Statistical Analyses
Descriptive analyses were performed for demographic and clinical char-
acteristics. Vitamin D deficiency was prespecified as plasma 25(OH)D lower
than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as  30
ng/mL.21 The association between vitamin D levels and patient characteristics
was described with percentages and medians and compared using the Wil-
coxon rank sum test and Kruskal-Wallis test. Correlations between plasma
25(OH)D and liver function tests and plasma IGF factors were calculated using
Spearman correlation coefficients.
The primary statistical analysis used to evaluate the association between
vitamin D status and patient outcome was the two-tailed linear test for trend,
using plasma 25(OH)D as a continuous variable,22 because the plasma
25(OH)D levels were generally consistent with a normal distribution, and in
order to avoid the possibility of selecting cut points with maximal P values. To
facilitate the display of our results, plasma 25(OH)D levels were defined in
quartiles. Logistic regression was used to calculate the relative risks for objec-
tive response adjusted for other patient and disease characteristics. Cox pro-
portional hazards modeling was used to calculate multivariate hazard ratios
(HR) and 95% CI.23 Collinearity of the covariates was assessed through corre-
lation indices and the condition matrix. The highest Pearson correlation be-
tween any two variables was 0.195, and the condition index of the multivariate
model was 25.3, suggesting that collinearity is not an issue of concern.
In secondary exploratory analyses, tests of interaction between plasma
25(OH)D and potential effect modifiers were assessed by entering in the model
the cross product term of 25(OH)D as a continuous variable with the covariate
as a continuous or binary variable. Analyses stratified by the dichotomized
covariate were performed using the initial quartile cutoffs that were calculated
for the entire cohort. Two-sided P values lower than .05 were used to denote
statistical significance. All analyses used SAS software, version 9.1 (SAS Insti-
tute Inc, Cary, NC).
RESULTS
Distribution of Vitamin D Levels
Baseline characteristics of the 515 included patients are presented
in Table 1. The median age was 61 years (range, 26 to 85), with 59%
males and 41% females. The vast majority of patients were white
(86%). The median plasma 25(OH)D level in the entire cohort was
20.0 ng/mL (range, 2.3 to 75.4 ng/mL) and the mean was 21.0 ng/mL
(SE of mean, 0.4 ng/mL). At the start of chemotherapy, 50% of the
study population were vitamin D deficient ( 20 ng/mL), and 82%
were vitamin D insufficient ( 30 ng/mL). Only 10% of patients had
plasma 25(OH)D levels  33 ng/mL, the threshold believed to be
required for a potential protective effect on colorectal cancer risk.24
Figure 2 summarizes the distribution of plasma 25(OH)D levels in the
study cohort.
Association of Vitamin D Levels With
Patient Characteristics
Plasma 25(OH)D levels were significantly lower in females com-
pared to males (median, 18.3 v 21.7 ng/mL, respectively; P  .0005;
Table 2). Plasma 25(OH)D levels were also significantly lower in black
patients compared to white patients and patients of other or unknown
race (median, 10.7, 21.1, and 19.3 ng/mL, respectively; P  .001).
Vitamin D deficiency was more common among black patients (80%)
compared with white patients (47%) and those of other or unknown
race (56%; P  .002). Moreover, only 4% of blacks, 11% of whites, and
9% of subjects of other or unknown race demonstrated plasma
25(OH)D levels  33 ng/mL. As expected, plasma 25(OH)D levels
varied significantly by season of blood collection (P  .001). Plasma
25(OH)D concentration was not significantly associated with patient
age, performance status, body mass index, chemotherapy arm, geo-
graphical region of registering site, number of metastatic sites, or
presence of liver metastases. Moreover, plasma 25(OH)D levels were
not significantly correlated with total bilirubin (r  0.03), alkaline
phosphatase (r  0.01), or aspartate aminotransferase (AST or
SGOT; r  0.03). We also explored the correlation between plasma
25(OH)D and levels of plasma IGF factors, since preclinical data
suggest that the two pathways may interact.25,26 No significant corre-
lations were detected between plasma 25(OH)D and IGF-1 (r  0.05),
IGF-2 (r  0.04), IGFBP-3 (r  0.002), or C-peptide (r  0.04).
Impact of Vitamin D Levels on Patient Outcome
Despite the finding that only 10% of our cohort demonstrated
plasma 25(OH)D levels  33 ng/mL at baseline, we still examined the
association between 25(OH)D levels and patient outcome. We did not
detect a significant relationship between higher levels of 25(OH)D and
overall survival, TTP, or tumor response (Table 3). Compared to
patients in the lowest quartile, those with plasma 25(OH)D levels in
the highest quartile had a multivariate HR for death of 0.94 (95% CI,
0.72 to 1.23; P trend  .55) and a multivariate HR for disease progres-
sion of 1.07 (95% CI, 0.81 to 1.42; P trend  .66). Higher vitamin D
levels were also not associated with improved tumor response (multi-
variate RR 1.12 comparing the highest to lowest quartile; 95% CI, 0.67
to 1.89; P trend  .67). Our results did not change appreciably when
we excluded poor performance status patients and those with body
mass index  23 kg/m2 (reflecting impaired nutritional status),20 or
when we additionally adjusted for geographic region.
Impact of Vitamin D Levels Across Strata of Other
Predictors of Patient Outcome
We examined the influence of plasma 25(OH)D on overall sur-
vival across strata of other predictors of cancer outcome (Fig 3). Most


















Fig 2. Distribution of serum 25-hydroxyvitamin D [25(OH)D] levels in the study
cohort (n  515).
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25(OH)D and survival, consistent with our primary analysis. How-
ever, a significant interaction was observed with treatment arm (P
interaction  .0005 using the likelihood ratio test). Among patients
randomly assigned to FOLFOX, higher levels of 25(OH)D were sig-
nificantly associated with improved survival (adjusted HR 0.64 com-
paring extreme quartiles; 95% CI, 0.45 to 0.90; P trend  .003); but
among those randomized to IFL, higher levels of 25(OH)D were
detrimental (adjusted HR, 2.41; 95% CI, 1.32 to 4.39; P trend  .008).
Plasma 25(OH)D was not significantly associated with survival in
patients randomly assigned to IROX.
We considered the possibility that the beneficial effect of higher
plasma 25(OH)D levels among patients receiving FOLFOX may sug-
gest that, in stage IV disease, an improved outcome associated with
higher vitamin D levels is limited to subjects who experience a reduc-
tion in tumor burden from chemotherapy. We therefore repeated the
subgroup analyses using a landmark analysis that adjusted for patients
with a confirmed tumor response at 18 weeks. However, our results
remained unchanged, with a persistent benefit of higher plasma
25(OH)D levels seen among patients randomly assigned to FOLFOX.
In an additional subgroup analysis, we observed a trend toward a
beneficial impact of higher 25(OH)D levels on survival in patients
with IGFBP-3 levels above the median (P interaction  .07). Signifi-
cant interactions were not detected for overall survival between
plasma 25(OH)D and IGF-1, IGF-2, and C-peptide.
Table 2. Relationship of 25(OH)D Levels to Selected Patient Characteristics




 61 244 47 20.0 2.3-52.2
 61 271 53 20.4 4.3-75.4
Sex .0005†
Female 209 41 18.3 2.3-55.4
Male 306 59 21.7 4.5-75.4
Race or ethnicity  .001‡
White 441 86 21.1 2.3-75.4
Black 40 8 10.7 4.3-49.8
Other/unknown 34 6 19.3 9.0-35.8
ECOG performance status .85†
0-1 493 96 21.1 2.3-75.4
2 22 4 19.3 7.1-32.1
Body mass index, kg/m2 § .17†
 26.1 253 49 21.1 2.3-75.4
 26.1 262 51 18.8 3.9-48.8
Treatment arm .51‡
IFL 112 22 18.6 5.1-75.4
FOLFOX 299 58 21.1 4.3-52.1
IROX 104 20 19.2 2.3-51.2
Season of blood collection  .001‡
Summer 140 27 22.6 4.3-49.4
Autumn 83 16 24.2 4.3-55.4
Winter 141 27 18.8 4.7-75.4
Spring 151 30 16.5 2.3-48.8
Geographic region of registering site¶ .82‡
Northeastern US  Canada 121 24 21.2 4.7-51.2
Midwestern US 238 47 19.0 2.3-75.4
Southern US  Puerto Rico 87 17 21.8 3.9-52.1
Western US 58 12 19.8 4.8-38.2
No. of metastatic sites .63†
 2 172 33 21.6 4.3-49.8
 2 343 67 19.6 3.2-75.4
Liver metastases .09†
Yes 410 80 19.2 2.3-75.4
No 103 20 23.0 6.0-49.8
Abbreviations: 25(OH)D, 25-hydroxyvitamin D3; ECOG, Eastern Cooperative Oncology Group; IFL, irinotecan, bolus fluorouracil, leucovorin; FOLFOX, fluorouracil,
leucovorin, oxaliplatin; IROX, irinotecan, oxaliplatin; US, United States.
Cut points chosen based on median values.
†P calculated using Wilcoxon rank sum test.
‡P calculated using Kruskal-Wallis test.
§Body mass index is calculated as weight in kilograms divided by height in meters squared. Body mass index was based on patient status at initiation of
chemotherapy (entry into treatment trial).
Seasons defined as: Summer  June, July, August; Autumn  September, October, November; Winter  December, January, February; Spring  March, April,
May.
¶Geographic regions defined according to the US Census Bureau: Northeast  CT, ME, MA, NH, NJ, NY, PA, RI, VT; Midwest  IL, IN, IA, KS, MI, MN, MO, NE,
ND, OH, SD, WI; South  AL, DE, FL, GA, KY, LA, MD, NC, OK, SC, TN, TX, VA, WV; West  AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.
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DISCUSSION
In this cohort of patients with previously untreated metastatic colorectal
cancer, we found a high prevalence of vitamin D deficiency, particularly
among black and female patients. Vitamin D insufficiency was seen in
82% of patients and vitamin D deficiency in 50%. Only 10% of patients
had plasma 25(OH)D levels  33 ng/mL, the threshold believed to be
required for a potential protective effect of vitamin D on colorectal cancer
risk.24 Only 8% of female and 4% of black patients achieved levels  33
ng/mL. Perhaps owing to this skewed distribution of 25(OH)D levels in
the cohort, higher plasma 25(OH)D levels were not significantly associ-
ated with improved overall survival, TTP, or tumor response. To our
knowledge, this is the first study to prospectively characterize the vitamin
D status of patients with stage IV colorectal cancer.
Our findings are consistent with a recent analysis of the National
Health and Nutrition Examination Survey (NHANES), which found a
low mean plasma 25(OH)D level of 24 ng/mL among 13,369 partici-
pants between 2001 and 2004.1 This represented a marked decrease
from NHANES III (1988 to 1994), when the mean 25(OH)D level was
30 ng/mL. Potential explanations for the rise in vitamin D insuffi-
ciency include increasing use of sunscreen for skin cancer prevention,
decreased outdoor activity, and the rising prevalence of obesity. Rates
of vitamin D insufficiency in our cohort were even higher than
NHANES, possibly reflecting an inverse association of plasma
25(OH)D with colorectal cancer incidence and/or dietary and lifestyle
changes after cancer diagnosis. A recent study of patients with stage I
to III breast cancer similarly described a high prevalence of vitamin D
deficiency and found that supplementation using standard dosage
guidelines (400 U daily) was inadequate for raising levels into the
sufficient range.27 The greater prevalence of vitamin D deficiency
among black patients in our cohort is consistent with other stud-
ies,1,27,28 and is largely explained by lower vitamin D synthesis in skin
due to greater melanin content.29 Melanin effectively filters ultraviolet
B radiation, although a reduced rate of conversion of cholecalciferol to
25(OH)D may also contribute. Differences in levels of plasma
25(OH)D may contribute to the greater incidence of and mortality
from colorectal cancer seen among African Americans.30
In the United States, colorectal cancer mortality follows a latitu-
dinal gradient, with higher mortality rates seen in individuals who
reside at higher latitudes.31-34 A large observational study in Norway
found that people diagnosed with colorectal cancer in the summer and
autumn, when 25(OH)D concentrations are highest, had significantly
better survival than those diagnosed in the winter.35,36 We previously
showed that higher prediagnosis plasma levels of 25(OH)D and higher
postdiagnostic 25(OH)D scores are associated with significant reduc-
tions in mortality among patients with established colorectal cancer,
although, in those studies, a substantially greater proportion of the
population had plasma 25(OH)D levels higher than 33 ng/mL.15,16
Inthisstudy,wedidnotdetectanassociationbetweenhigherplasma
25(OH)D and patient outcome. It is possible that vitamin D may have
limited impact on the natural history of colorectal cancer once it has
metastasized. Preclinical data indicate that VDR expression is decreased
Table 3. Impact of 25(OH)D on Overall Survival, Time to Progression, and Confirmed Tumor Response
Parameter
Plasma 25(OH)D (ng/mL) by Quartile
P for Trend†1 2 3 4
Overall survival
No. at risk 128 128 129 130
No. of events 121 114 118 122
Age- and season-adjusted HR Referent 0.86 1.00 0.99 .81
95% CI 0.66 to 1.11 0.78 to 1.30 0.77 to 1.29
Multivariate HR‡ Referent 0.78 1.13 0.94 .55
95% CI 0.60 to 1.02 0.87 to 1.47 0.72 to 1.23
Time to progression
No. at risk 128 128 129 130
No. of events 106 114 110 110
Age- and season-adjusted HR Referent 1.17 1.17 1.14 .97
95% CI 0.90 to 1.53 0.89 to 1.53 0.86 to 1.49
Multivariate HR‡ Referent 1.14 1.23 1.07 .66
95% CI 0.87 to 1.49 0.93 to 1.62 0.81 to 1.42
Confirmed response
No. at risk 128 126 128 129
No. of events 56 60 59 64
Age- and season-adjusted RR Referent 1.12 1.05 1.15 .59
95% CI 0.68 to 1.84 0.64 to 1.72 0.70 to 1.91
Multivariate RR‡ Referent 1.15 0.98 1.12 .67
95% CI 0.70 to 1.91 0.59 to 1.63 0.67 to 1.89
Abbreviations: 25(OH)D, 25-hydroxyvitamin D3; HR, hazard ratio; RR, relative risk; IFL, irinotecan, bolus fluorouracil, leucovorin; FOLFOX, fluorouracil, leucovorin,
oxaliplatin; IROX, irinotecan, oxaliplatin.
Quartile 1, 2.3-13.1 ng/mL; quartile 2, 13.2-19.9 ng/mL; quartile 3, 20.0-27.1 ng/mL; quartile 4, 27.2-75.4 ng/mL.
†Calculated by using 25(OH)D as a continuous variable.
‡Adjusted for age (in years as a continuous variable), season of blood collection (summer, autumn, winter, spring), sex (male, female), baseline performance status
(0-1, 2), treatment arm (IFL, FOLFOX4, IROX), body mass index (in kg/m2 as a continuous variable), and metastatic sites (liver only, liver  any other site, single
non-liver, multiple non-liver).
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in late stages of neoplasia,37 perhaps leading to loss of response of colon
tumor cells to vitamin D. Yet another potential explanation for the dis-
crepant results is that our study had limited statistical power, with only a
small number of patients with plasma 25(OH)D levels sufficient for a
protective effect on cancer outcome.24 Indeed, based on the distribution
of vitamin D levels ultimately found in this cohort, we had only a 15% to
20% power38 to detect an improvement in overall survival comparable to
the findings of prior studies.15,16
Our exploratory analyses revealed that patients with stage IV
colorectal cancer randomly assigned to FOLFOX may have improved
survival with higher baseline levels of 25(OH)D, whereas those ran-
domly assigned to IFL had worse survival. Given the limited number
of patients in this subgroup analysis, our findings may simply be due
to chance. However, in vitro and in vivo analyses suggest that
1,25(OH)2D may potentiate the antineoplastic effects of platinum
agents.39-41 We also considered the possibility that vitamin D may
have a greater impact on outcome in tumors that respond to chemo-
therapy, but our results did not change when we adjusted our analysis
for patients with confirmed tumor response at 18 weeks. These find-
ings in patients on FOLFOX require confirmation in other cohorts.
We also detected a trend toward an interaction between plasma
25(OH)D levels and baseline plasma IGFBP-3. Given that higher
levels of IBFBP-3 were previously found to be significantly associated
with patient outcome in this cohort,20 further study of the interaction
between the vitamin D and IGF pathways is warranted.
Analyzing patients participating in a National Cancer Institute–
sponsored trial, we were able to assess plasma 25(OH)D levels across a
large cohort of patients with stage IV colorectal cancer across North
America. In addition, the vitamin D assay that we used had high
precision. Nonetheless, several potential limitations deserve com-
ment. Baseline 25(OH)D levels may be influenced by morbidity from
recent surgery or burden of cancer, particularly in the liver, and may
therefore not reflect true vitamin D status. However, as part of the
clinical trial, all patients were required to have adequate biochemical
parameters for enrollment, including total bilirubin  1.5 times the
institutional upper limit of normal and AST and alkaline phospha-
tase  5 times the institutional upper limit of normal.17 Moreover,
vitamin D levels were not significantly associated with liver function
tests or the presence of liver metastases. Consequently, it is unlikely
that the low levels of plasma 25(OH)D seen in our cohort are ex-
plained by the presence of liver metastases. Another potential limita-
tion is that plasma 25(OH)D levels were only measured at the start of
chemotherapy; as such, the impact of changes in these levels on patient
outcome could not be assessed.
In conclusion, we found a high prevalence of vitamin D insuffi-
ciency ( 80%) among patients with metastatic colorectal cancer
undergoing first-line chemotherapy, particularly in female and black
patients. Ultimately, the relative inadequacy of vitamin D levels in this
population may have precluded a robust examination of the associa-
tion between baseline levels and patient outcome. Further study of the
impact of optimizing vitamin D status in patients with stage IV colo-
rectal cancer is warranted.
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irinotecan, oxaliplatin; IGF, insulin-like growth factor; IGFBP, IGF binding protein.
Vitamin D Status in Stage IV Colorectal Cancer
www.jco.org © 2011 by American Society of Clinical Oncology 1605
Manuscript writing: Kimmie Ng, Daniel J. Sargent, Richard M.
Goldberg, Jeffrey A. Meyerhardt, Erin M. Green, Henry C. Pitot, Bruce
W. Hollis, Michael N. Pollak, Charles S. Fuchs
Final approval of manuscript: Kimmie Ng, Daniel J. Sargent, Richard
M. Goldberg, Jeffrey A. Meyerhardt, Erin M. Green, Henry C. Pitot,
Bruce W. Hollis, Michael N. Pollak, Charles S. Fuchs
REFERENCES
1. Ginde AA, Liu MC, Camargo CA Jr: Demo-
graphic differences and trends of vitamin D insuffi-
ciency in the US population, 1988-2004. Arch Intern
Med 169:626-632, 2009
2. Lappe JM, Travers-Gustafson D, Davies KM,
et al: Vitamin D and calcium supplementation re-
duces cancer risk: Results of a randomized trial.
Am J Clin Nutr 85:1586-1591, 2007
3. Trivedi DP, Doll R, Khaw KT: Effect of four
monthly oral vitamin D3 (cholecalciferol) supplemen-
tation on fractures and mortality in men and women
living in the community: Randomised double blind
controlled trial. BMJ 326:469, 2003
4. Meggouh F, Lointier P, Saez S: Sex steroid
and 1,25-dihydroxyvitamin D3 receptors in human
colorectal adenocarcinoma and normal mucosa.
Cancer Res 51:1227-1233, 1991
5. Vandewalle B, Adenis A, Hornez L, et al:
1,25-dihydroxyvitamin D3 receptors in normal and
malignant human colorectal tissues. Cancer Lett
86:67-73, 1994
6. Zehnder D, Bland R, Williams MC, et al:
Extrarenal expression of 25-hydroxyvitamin d(3)-1
alpha-hydroxylase. J Clin Endocrinol Metab 86:888-
894, 2001
7. Vandewalle B, Wattez N, Lefebvre J: Effects
of vitamin D3 derivatives on growth, differentiation
and apoptosis in tumoral colonic HT 29 cells: Possi-
ble implication of intracellular calcium. Cancer Lett
97:99-106, 1995
8. Diaz GD, Paraskeva C, Thomas MG, et al:
Apoptosis is induced by the active metabolite of
vitamin D3 and its analogue EB1089 in colorectal
adenoma and carcinoma cells: Possible implications
for prevention and therapy. Cancer Res 60:2304-
2312, 2000
9. Scaglione-Sewell BA, Bissonnette M, Skarosi
S, et al: A vitamin D3 analog induces a G1-phase
arrest in CaCo-2 cells by inhibiting cdk2 and cdk6:
roles of cyclin E, p21Waf1, and p27Kip1. Endocrinol-
ogy 141:3931-3939, 2000
10. Iseki K, Tatsuta M, Uehara H, et al: Inhibition of
angiogenesis as a mechanism for inhibition by 1alpha-
hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of co-
lon carcinogenesis induced by azoxymethane in Wistar
rats. Int J Cancer 81:730-733, 1999
11. Fernandez-Garcia NI, Palmer HG, Garcia M, et
al: 1alpha,25-Dihydroxyvitamin D3 regulates the ex-
pression of Id1 and Id2 genes and the angiogenic
phenotype of human colon carcinoma cells. Onco-
gene 24:6533-6544, 2005
12. Lamprecht SA, Lipkin M: Cellular mecha-
nisms of calcium and vitamin D in the inhibition of
colorectal carcinogenesis. Ann N Y Acad Sci 952:73-
87, 2001
13. Evans SR, Shchepotin EI, Young H, et al: 1,25-
dihydroxyvitamin D3 synthetic analogs inhibit spontane-
ous metastases in a 1,2-dimethylhydrazine-induced
colon carcinogenesis model. Int J Oncol 16:1249-1254,
2000
14. Deeb KK, Trump DL, Johnson CS: Vitamin D
signalling pathways in cancer: Potential for antican-
cer therapeutics. Nat Rev Cancer 7:684-700, 2007
15. Ng K, Meyerhardt JA, Wu K, et al: Circulating
25-hydroxyvitamin d levels and survival in patients
with colorectal cancer. J Clin Oncol 26:2984-2991,
2008
16. Ng K, Wolpin BM, Meyerhardt JA, et al:
Prospective study of predictors of vitamin D status
and survival in patients with colorectal cancer. Br J
Cancer 101:916-923, 2009
17. Goldberg RM, Sargent DJ, Morton RF, et al: A
randomized controlled trial of fluorouracil plus leuco-
vorin, irinotecan, and oxaliplatin combinations in
patients with previously untreated metastatic colo-
rectal cancer. J Clin Oncol 22:23-30, 2004
18. Meyerhardt JA, Sloan JA, Sargent DJ, et al:
Associations between plasma insulin-like growth
factor proteins and C-peptide and quality of life in
patients with metastatic colorectal cancer. Cancer
Epidemiol Biomarkers Prev 14:1402-1410, 2005
19. Hollis BW: Quantitation of 25-hydroxyvitamin
D and 1,25-dihydroxyvitamin D by radioimmunoas-
say using radioiodinated tracers. Methods Enzymol
282:174-186, 1997
20. Fuchs CS, Goldberg RM, Sargent DJ, et al:
Plasma insulin-like growth factors, insulin-like bind-
ing protein-3, and outcome in metastatic colorectal
cancer: Results from intergroup trial N9741. Clin
Cancer Res 14:8263-8269, 2008
21. Holick MF: Vitamin D status: Measurement,
interpretation, and clinical application. Ann Epide-
miol 19:73-78, 2009
22. Kleinbaum DG, Kupper LL, Nizam A, et al:
Applied regression analysis and other multivariable
methods (ed 4). Belmont, CA, Thomson Learning
Inc, 2008
23. Cox DR: Regression models and life tables
[with discussion]. J Royal Stat Soc (B) 34:187-220,
1972
24. Gorham ED, Garland CF, Garland FC, et al:
Optimal vitamin D status for colorectal cancer pre-
vention: A quantitative meta analysis. Am J Prev
Med 32:210-216, 2007
25. Huynh H, Pollak M, Zhang JC: Regulation of
insulin-like growth factor (IGF) II and IGF binding
protein 3 autocrine loop in human PC-3 prostate
cancer cells by vitamin D metabolite 1,25(OH)2D3
and its analog EB1089. Int J Oncol 13:137-143, 1998
26. Ma J, Giovannucci E, Pollak M, et al: Milk
intake, circulating levels of insulin-like growth
factor-I, and risk of colorectal cancer in men. J Natl
Cancer Inst 93:1330-1336, 2001
27. Crew KD, Shane E, Cremers S, et al: High
prevalence of vitamin D deficiency despite supple-
mentation in premenopausal women with breast
cancer undergoing adjuvant chemotherapy. J Clin
Oncol 27:2151-2156, 2009
28. Nesby-O’Dell S, Scanlon KS, Cogswell ME, et
al: Hypovitaminosis D prevalence and determinants
among African American and white women of re-
productive age: Third National Health and Nutrition
Examination Survey, 1988-1994. Am J Clin Nutr
76:187-192, 2002
29. Clemens TL, Adams JS, Henderson SL, et al:
Increased skin pigment reduces the capacity of skin
to synthesise vitamin D3. Lancet 1:74-76, 1982
30. American Cancer Society: Cancer Facts and
Figures for African Americans 2009-2010. Atlanta,
GA, American Cancer Society, 2009
31. Grant WB: An estimate of premature cancer
mortality in the U.S. due to inadequate doses of
solar ultraviolet-B radiation. Cancer 94:1867-1875,
2002
32. Garland CF, Garland FC: Do sunlight and vita-
min D reduce the likelihood of colon cancer? Int J
Epidemiol 9:227-231, 1980
33. Grant WB: Ecologic studies of solar UV-B
radiation and cancer mortality rates. Recent Results
Cancer Res 164:371-377, 2003
34. Devesa SS, Grauman MA, Blot WJ, et al: Atlas
of Cancer Mortality in the United States: 1950-1994.
Bethesda, MD, National Cancer Institute, NIH pub-
lication 99-4564, 1999
35. Robsahm TE, Tretli S, Dahlback A, et al:
Vitamin D3 from sunlight may improve the progno-
sis of breast-, colon- and prostate cancer (Norway).
Cancer Causes Control 15:149-158, 2004
36. Moan J, Porojnicu AC, Robsahm TE, et al:
Solar radiation, vitamin D and survival rate of colon
cancer in Norway. J Photochem Photobiol B 78:189-
193, 2005
37. Shabahang M, Buras RR, Davoodi F, et al:
1,25-Dihydroxyvitamin D3 receptor as a marker of
human colon carcinoma cell line differentiation and
growth inhibition. Cancer Res 53:3712-3718, 1993
38. Rosner B: Fundamentals of Biostatistics (ed
4). Belmont, CA, Duxbury Press, 1995
39. Hershberger PA, McGuire TF, Yu WD, et al:
Cisplatin potentiates 1,25-dihydroxyvitamin D3-
induced apoptosis in association with increased
mitogen-activated protein kinase kinase kinase 1
(MEKK-1) expression. Mol Cancer Ther 1:821-829,
2002
40. Light BW, Yu WD, McElwain MC, et al: Po-
tentiation of cisplatin antitumor activity using a vita-
min D analogue in a murine squamous cell
carcinoma model system. Cancer Res 57:3759-
3764, 1997
41. Moffatt KA, Johannes WU, Miller GJ:
1Alpha,25dihydroxyvitamin D3 and platinum drugs
act synergistically to inhibit the growth of prostate
cancer cell lines. Clin Cancer Res 5:695-703, 1999
■ ■ ■
Ng et al
1606 © 2011 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
